Saruparib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Prostate Cancer. According to GlobalData, Phase III drugs for Metastatic Prostate Cancer have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Saruparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Saruparib overview
Saruparib (AZD-5305) is under development for the treatment of advanced solid tumors including triple-negative breast cancer, HER2 negative breast cancer, pancreatic cancer, prostate cancer, metastatic prostate cancer (metastatic castration-sensitive prostate cancer), ovarian cancer. fallopian tube cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, endometrial cancer, gastric cancer, small-cell lung cancer, esophageal cancer, transitional cell cancer (urothelial cell cancer) and primary peritoneal cancer. It is administered through oral route and acts by targeting Poly (ADP-ribose) polymerase (PARP1).
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Saruparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
